🔗 Share this article

Given that America continues making unprecedented adjustments to its immunization schedules, an unexpected name appears somewhat surprisingly: Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by casting doubt on coronavirus vaccinations in the pandemic and has concentrated on alleged deaths following Covid vaccination in her recent position at the Food and Drug Administration.

Scheduled Changes to Childhood Vaccine Program

Health officials had intended to unveil sweeping changes to the childhood immunization program recently, bringing the US with Denmark’s immunization schedule, it is understood – a substantial departure that would place the US out of step with a large portion of the global community with little proof for improved outcomes. The planned update has been pushed back until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this calendar year.

A Shift at the Agency

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a renewed priority upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has often pushed for ending certain pediatric vaccine recommendations in the US so as to align more similar to Denmark, a nation with universal health coverage and a number of inhabitants about the population of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccines – usually the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Background

Høeg has no apparent track record in medication creation, oversight or leadership, which has been typical for past leaders of the CBER. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She has not conducted a scientific study. She is not versed in leading a large organization. She has no expertise in pharmaceutical oversight.”

Former heads of CBER would “grasp legal statutes and the underlying principles of medication creation”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that former directors who led the center have had.”

This division has an vast portfolio at the FDA, Woodcock stated.

“The public just focuses on the novel medication approvals, but the generic program clears numerous off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and more, and every single one must be managed,” Woodcock said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a major administrative component to the position, which oversees in excess of 5,000 personnel. “It is a huge leadership role, if you execute it properly,” the former official added.

Agency Reaction and Contentious Initiatives

Regarding inquiries about Dr. Høeg's fitness for the role and whether this assignment signifies more teamwork among FDA leaders on vaccines, a representative stated that the “inquiries are based on incorrect presumptions”.

“Her experience matches the duties of her position,” the spokesperson explained, noting the months Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg takes over the agency head's new fast-track approval initiative, a contentious one-day drug-approval program that reportedly worried her predecessors. “How are these drugs being picked for this voucher program? Who takes the decisions?” Howard said. “There’s a lot of secrecy occurring at the FDA right now.”

In general, he stated, “the agency seems to be moving towards less stringent oversight of most medications, except for shots.”

Documented Past Work on Immunizations

Concerning vaccines, Høeg has a more established, if troubling, past, Howard have noted. She authored a research paper using unconfirmed public submissions to assess the incidence of myocarditis following Covid vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Part of her “policy goals” for the incoming government included altering guidelines for new vaccines and halting “unnecessary” immunizations, she remarked post-election on a podcast. At the FDA, Dr. Høeg has according to sources suggested barring teenage boys from getting COVID-19 vaccines.

“She is an all-around dogmatist who begins with her preconceived notions and reverse-engineers to accommodate the evidence in a highly misleading, dishonest way,” Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of fellow contrarians, {like|